Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Expected To Reach $8.97 Billion By 2030 As Growth Accelerates At 8.2% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics has experienced robust expansion in recent years. Projected to rise from $6.11 billion in 2025 to $6.55 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 7.1%. Historical expansion has been driven by factors such as a higher incidence of chronic pancreatitis, growing public awareness of digestive health issues, restricted availability of specialized diagnostic tools, increased use of nutritional supplements, and the broadening reach of home healthcare services.
The market for exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics is projected to experience robust expansion in the coming years. By 2030, its value is anticipated to reach $8.97 billion, driven by a compound annual growth rate (CAGR) of 8.2%. This forecasted growth is influenced by progress made in customizing enzyme therapies, the incorporation of artificial intelligence into diagnostic tools, an increased need for imaging methods that are non-invasive, the broadening of telehealth services, and a heightened emphasis on nutrition management tailored to individual patients. Key developments shaping this period include improved forms of pancreatic enzyme replacement therapy, rapid diagnostic tools usable at the point of care, customized nutritional care plans, imaging techniques that avoid invasive procedures for EPI, and the widespread adoption of telehealth within EPI treatment protocols.
Download A Free Sample Report For Comprehensive Market Insights:
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Drivers: What Factors Are Accelerating Expansion?
The rising prevalence of diabetes is anticipated to drive expansion in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the coming period. Diabetes is defined as a chronic metabolic condition marked by sustained high blood sugar levels (hyperglycemia) over an extended timeframe. This disorder arises when the body fails to generate sufficient insulin or cannot utilize the insulin it produces effectively. EPI treatment, primarily through pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption in individuals with both diabetes and EPI. Additionally, it may support better glycemic control in diabetic patients. For example, in June 2024, data from The National Health Service (NHS England), a publicly funded healthcare system in the UK, revealed that in 2023, the count of individuals identified with pre-diabetes in England climbed to 3,615,330, representing an 18% rise from 3,065,825 in 2022. Moreover, among those under 40, cases surged by nearly 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing number of diabetes cases is fueling the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
The growing frequency of gastrointestinal disorders is expected to boost the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market moving forward. Gastrointestinal diseases encompass a range of medical conditions impacting the gastrointestinal tract, which includes organs involved in digestion. EPI therapeutics and diagnostics are essential for managing these diseases by targeting the root enzyme deficiency and facilitating proper nutrient digestion. They play a key role in gastrointestinal disease management by correcting enzyme shortages and aiding digestive processes. As an illustration, in June 2023, Crohn’s and Colitis Canada, a non-profit organization based in Canada, reported that over 322,600 Canadians were estimated to be living with inflammatory bowel diseases (IBD) in 2023, accounting for roughly 0.82% of the population. With the ongoing rise in IBD prevalence, projections indicate that approximately 470,000 Canadians will have IBD by 2035, equating to about 1.1% of the population, or one in every 91 individuals nationwide. Thus, the escalating incidence of gastrointestinal diseases is anticipated to drive growth in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segment Analysis: What Are The Major Market Categories?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends: What Is Shaping Future Industry Growth?
Major players within the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are actively leveraging a strategic partnership approach to drive better technology integration and broaden their market presence. This type of arrangement generally involves a collaborative alliance between multiple organizations, where they pool their resources, specialized knowledge, and collective efforts to achieve shared goals or objectives. A case in point is February 2023, when Codexis, Inc., a protein engineering firm based in the United States, joined forces with Nestlé Health Science, a Swiss company focused on nutritional science, to release interim findings from their Phase 1 clinical trial for CDX-7108—an investigational therapy designed to manage exocrine pancreatic insufficiency (EPI). These outcomes from the Phase 1 trial lay a solid foundation for subsequent investigations that could potentially lead to significant enhancements in treatment options for individuals dealing with EPI.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Leading Companies Driving Competitive Growth
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd
Access The Complete Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
